Lupin gets US FDA nod for Epileptic drug

20 Oct 2011 Evaluate

Lupin Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) to market the generic version of the anti-epileptic drug Keppra. The total sales of this drug in the US market is estimated to be $13 billion. Keppra was the patented drug of European drug maker UCB pharma. It lost the patent for this drug in 2008. The drug has been growing at 23% every year with a total sales of $1.74 billion

Lupin Share Price

2137.15 -27.90 (-1.29%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×